996 related articles for article (PubMed ID: 33626922)
1. Migraine therapeutics differentially modulate the CGRP pathway.
Bhakta M; Vuong T; Taura T; Wilson DS; Stratton JR; Mackenzie KD
Cephalalgia; 2021 Apr; 41(5):499-514. PubMed ID: 33626922
[TBL] [Abstract][Full Text] [Related]
2. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
Tepper SJ
Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
[TBL] [Abstract][Full Text] [Related]
3. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
[TBL] [Abstract][Full Text] [Related]
4. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
Chiang CC; Schwedt TJ
Prog Brain Res; 2020; 255():143-170. PubMed ID: 33008505
[TBL] [Abstract][Full Text] [Related]
5. Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class.
Hargreaves R; Olesen J
Headache; 2019 Jun; 59(6):951-970. PubMed ID: 31020659
[TBL] [Abstract][Full Text] [Related]
6. CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention.
Caronna E; Alpuente A; Torres-Ferrus M; Pozo-Rosich P
Handb Clin Neurol; 2024; 199():107-124. PubMed ID: 38307640
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex.
Porreca F; Navratilova E; Hirman J; van den Brink AM; Lipton RB; Dodick DW
Cephalalgia; 2024 Mar; 44(3):3331024241238153. PubMed ID: 38477313
[TBL] [Abstract][Full Text] [Related]
8. Role of Monoclonal Antibodies against Calcitonin Gene-Related Peptide (CGRP) in Episodic Migraine Prevention: Where Do We Stand Today?
Nagaraj K; Vandenbussche N; Goadsby PJ
Neurol India; 2021; 69(Supplement):S59-S66. PubMed ID: 34003149
[TBL] [Abstract][Full Text] [Related]
9. Medications Approved for Preventing Migraine Headaches.
Spindler BL; Ryan M
Am J Med; 2020 Jun; 133(6):664-667. PubMed ID: 32145209
[TBL] [Abstract][Full Text] [Related]
10. Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives.
De Matteis E; Guglielmetti M; Ornello R; Spuntarelli V; Martelletti P; Sacco S
Expert Rev Neurother; 2020 Jun; 20(6):627-641. PubMed ID: 32434430
[TBL] [Abstract][Full Text] [Related]
11. Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018.
Tepper SJ
Headache; 2018 Nov; 58 Suppl 3():276-290. PubMed ID: 30403405
[TBL] [Abstract][Full Text] [Related]
12. Characterization of erenumab and rimegepant on calcitonin gene-related peptide induced responses in Xenopus Laevis oocytes expressing the calcitonin gene-related peptide receptor and the amylin-1 receptor.
Hage La Cour S; Juhler K; Kogelman LJA; Olesen J; Klærke DA; Kristensen DM; Jansen-Olesen I
J Headache Pain; 2022 May; 23(1):59. PubMed ID: 35614383
[TBL] [Abstract][Full Text] [Related]
13. Role of Calcitonin Gene-Related Peptide on the Gastrointestinal Symptoms of Migraine-Clinical Considerations: A Narrative Review.
Ailani J; Kaiser EA; Mathew PG; McAllister P; Russo AF; Vélez C; Ramajo AP; Abdrabboh A; Xu C; Rasmussen S; Tepper SJ
Neurology; 2022 Nov; 99(19):841-853. PubMed ID: 36127137
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans.
de Vries T; Villalón CM; MaassenVanDenBrink A
Pharmacol Ther; 2020 Jul; 211():107528. PubMed ID: 32173558
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological characterisation of erenumab, Aimovig, at two calcitonin gene-related peptide responsive receptors.
Garelja ML; Alexander TI; Bennie A; Nimick M; Petersen J; Walker CS; Hay DL
Br J Pharmacol; 2024 Jan; 181(1):142-161. PubMed ID: 37580864
[TBL] [Abstract][Full Text] [Related]
16. CGRP as the target of new migraine therapies - successful translation from bench to clinic.
Edvinsson L; Haanes KA; Warfvinge K; Krause DN
Nat Rev Neurol; 2018 Jun; 14(6):338-350. PubMed ID: 29691490
[TBL] [Abstract][Full Text] [Related]
17. Safety and Tolerability of 3 CGRP Monoclonal Antibodies in Practice: A Retrospective Cohort Study.
Alex A; Vaughn C; Rayhill M
Headache; 2020 Nov; 60(10):2454-2462. PubMed ID: 32969035
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study.
Jakate A; Blumenfeld AM; Boinpally R; Butler M; Borbridge L; Contreras-De Lama J; McGeeney D; Periclou A; Lipton RB
Headache; 2021 Apr; 61(4):642-652. PubMed ID: 33818780
[TBL] [Abstract][Full Text] [Related]
19. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention.
Sacco S; Bendtsen L; Ashina M; Reuter U; Terwindt G; Mitsikostas DD; Martelletti P
J Headache Pain; 2019 Jan; 20(1):6. PubMed ID: 30651064
[TBL] [Abstract][Full Text] [Related]
20. Emerging drugs for the preventive treatment of migraine: a review of CGRP monoclonal antibodies and gepants trials.
Silvestro M; Orologio I; Siciliano M; Trojsi F; Tessitore A; Tedeschi G; Russo A
Expert Opin Emerg Drugs; 2023 Dec; 28(2):79-96. PubMed ID: 37185047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
